For immediate release |
2 April 2019 |
RNS REACH
Evgen Pharma plc
("Evgen" or "the Company")
finnCap publishes initiation research
Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that finnCap, the Company's broker, has this morning initiated research on the Company. The research report is available to all by registering at finnCap's research portal: https://researchlibrary.finncap.com/
The report provides a comprehensive introduction to Evgen and its proprietary sulforaphane-based technology platform along with discussing in detail the Company's recent positive Phase II data in metastatic breast cancer and ongoing Phase II trial in subarachnoid haemorrhage.
Enquiries:
Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com |
c/o +44 (0) 20 7466 5000 |
finnCap Geoff Nash, Teddy Whiley (Corporate Finance) Alice Lane, Manasa Patil (ECM) www.finncap.com |
+44 (0) 20 7220 0500 |
WG Partners LLP Nigel Barnes, Claes Spång |
+44 (0) 20 3705 9330 |
Buchanan Mark Court, Sophie Wills, Tilly Abraham [email protected] |
+44 (0) 20 7466 5000 |
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
